Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation

Journal of Clinical Oncology

Volumn 34, Issue 30, 2016, Pages 3627-3637

  Della Porta, Matteo G ^a,b   Gallì, Anna ^a   Bacigalupo, Andrea ^c   Zibellini, Silvia ^a   Bernardi, Massimo ^d   Rizzo, Ettore ^a   Allione, Bernardino ^f   Van Lint, Maria Teresa ^c   Pioltelli, Pietro ^g   Marenco, Paola ^e   Bosi, Alberto ^h   Voso, Maria Teresa ⁱ   Sica, Simona ⁱ   Cuzzola, Mariella ^j   Angelucci, Emanuele ^k   Rossi, Marianna ^a   Ubezio, Marta ^a   Malovini, Alberto ^b   Limongelli, Ivan ^b   Ferretti, Virginia V ^a   Spinelli, Orietta ^l   Tresoldi, Cristina ^d   Pozzi, Sarah ^c   Luchetti, Silvia ^c   Pezzetti, Laura ^e   Catricalà, Silvia ^a   Milanesi, Chiara ^a   Riva, Alberto ^o   Bruno, Benedetto ^f   Ciceri, Fabio ^d   Bonifazi, Francesca ^m   Bellazzi, Riccardo ^b   Papaemmanuil, Elli ^p   Santoro, Armando ⁿ   Alessandrino, Emilio P ^a   Rambaldi, Alessandro ^l   Cazzola, Mario ^a,b   more..

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^k Ospedale Oncologico A Businco   (Italy)

^l Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ HUMANITAS UNIVERSITY   (Italy)

^o UNIVERSITY OF FLORIDA   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; BCOR PROTEIN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; PROTEIN; PROTEIN P53; SF3B1 PROTEIN; SRSF2 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL OUTCOME; CYTOGENETICS; DE NOVO ACUTE MYELOID LEUKEMIA; DNA SEQUENCE; DYSPLASIA; FEMALE; GENE MUTATION; GENE ONTOLOGY; GENETIC RISK; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; RNA SPLICING; SOMATIC MUTATION;

EID: 84992425369     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.3616     Document Type: Article

References (30)

1. Adès L, Itzykson R, Fenaux P: Myelodysplastic syndromes. Lancet 383:2239-2252, 2014
2. Papaemmanuil E, Cazzola M, Boultwood J, et al: Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365:1384-1395, 2011
3. Yoshida K, Sanada M, Shiraishi Y, et al: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69, 2011
4. Cazzola M, Della Porta MG, Malcovati L: The genetic basis of myelodysplasia and its clinical relevance. Blood 122:4021-4034, 2013
5. Malcovati L, Hellström-Lindberg E, Bowen D, et al: Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood 122:2943-2964, 2013
6. Della Porta MG, Tuechler H, Malcovati L, et al: Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 29:1502-1513, 2015
7. Greenberg PL, Tuechler H, Schanz J, et al: Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 120:2454-2465, 2012
8. Deeg HJ, Shulman HM, Anderson JE, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188-1194, 2000
9. Sierra J, Pérez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002
10. Alessandrino EP, Della Porta MG, Bacigalupo A, et al: WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895-902, 2008
11. Lim Z, Brand R, Martino R, et al: Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28:405-411, 2010
12. Della Porta MG, Alessandrino EP, Bacigalupo A, et al: Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 123:2333-2342, 2014
13. Della Porta MG, Travaglino E, Boveri E, et al: Minimal morphological criteria for defining bone marrow dysplasia: A basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 29:66-75, 2015
14. Papaemmanuil E, Gerstung M, Malcovati L, et al: Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616-3627, 2013; quiz 3699
15. Bejar R, Stevenson K, Abdel-Wahab O, et al: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011
16. Gerstung M, Pellagatti A, Malcovati L, et al: Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun 6:5901, 2015
17. Jädersten M, Saft L, Smith A, et al: TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. J Clin Oncol 29:1971-1979, 2011
18. Bejar R, Stevenson KE, Caughey B, et al: Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stemcell transplantation. J Clin Oncol 32:2691-2698, 2014
19. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
20. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007
21. Li H, Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26:589-595, 2010
22. DePristo MA, Banks E, Poplin R, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491-498, 2011
23. Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219, 2013
24. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
25. Logan BR, Zhang MJ, Klein JP: Regression models for hazard rates versus cumulative incidence probabilities in hematopoietic cell transplantation data. Biol Blood Marrow Transplant 12 (1, Suppl 1) 107-112, 2006
26. Lindsley RC, Mar. BG, Mazzola E, et al: Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367-1376, 2015
27. Ballman KV: Biomarker: Predictive or prognostic? J Clin Oncol 33:3968-3971, 2015
28. Walter MJ, Shen D, Ding L, et al: Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366:1090-1098, 2012
29. Kröger N: Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 119:5632-5639, 2012
30. Stone RM: How I treat patients with myelodysplastic syndromes. Blood 113:6296-6303, 2009